THREE SECTORS. SPECIFIC DRIVERS. MEASURABLE OUTCOMES.
Focused sector specialists. Not any sector generalists.
Straterra's mission is to improve human health outcomes. We focus where enterprise value is shaped by evidence, execution, capital efficiency, and transaction readiness in MedTech, Digital Health, and Life Sciences.
Each sector has its own valuation grammar. We translate that grammar into focused interventions: the financial, operational, governance, and evidence-building work required for investor, acquirer, and board confidence.
MEDTECH
Long pathways. Capital-intensive scale. Evidence that has to hold up.
PAIN POINTS
Long clinical and regulatory pathways
Capital-intensive scale to commercialisation
FDA, TGA, and CE milestones that gate value
IP strength and freedom-to-operate scrutiny
Distribution leverage and channel economics
VALUATION DRIVERS
IP strength and defensibility
Clinical evidence quality
Regulatory clearance trajectory
Distribution leverage
Transaction-grade governance and reporting
STRATERRA CONTRIBUTION
We help MedTech leaders prioritise the financial, operational, governance, and evidence-building work required to support valuation and transaction readiness. We work as an operating partner to leadership through milestone gates rather than producing detached advisory output.
DIGITAL HEALTH
Recurring revenue that has to be earned. Evidence that has to be defensible.
PAIN POINTS
Reimbursement complexity
Evidence requirements across payers and providers
B2B2C sales cycles and pilot-to-contract conversion
Deployment scalability
Data defensibility
VALUATION DRIVERS
Recurring revenue quality
Deployment scalability
Payer and provider stickiness
Data defensibility
Unit economics under scale
STRATERRA CONTRIBUTION
We help Digital Health teams convert market traction into a clearer value story, a stronger operating model, and a more defensible narrative for investors or acquirers. Our focus is on the financial and operational discipline behind the growth, not the growth story alone.
LIFE SCIENCES
Evidence-led, capital-intensive, and increasingly transaction-driven.
PAIN POINTS
Long development and validation cycles
Capital intensity across discovery, development, and scale
Translational and clinical evidence requirements
IP and platform defensibility
Partnering, licensing, and channel complexity
VALUATION DRIVERS
Platform and IP strength
Evidence quality across translational and clinical stages
Capital efficiency and runway discipline
Partnering and licensing economics
Transaction-grade governance and reporting
STRATERRA CONTRIBUTION
We help Life Sciences leaders sharpen the commercial, financial, and operational drivers that demonstrate durable value beyond near-term scientific milestones. We work as an operating partner to leadership through R&D, capital, and partnering decisions, with a particular focus on Australian R&D operating structures and R&DTI pathways where relevant.
Three sectors. One operating discipline.
Across MedTech, Digital Health, and Life Sciences, Straterra applies the same value-creation discipline: identify the drivers suppressing enterprise value, implement the highest-impact changes, and measure progress against an investor-grade scorecard. The sector lens changes. The discipline does not.